This bill mandates that all health insurers in New Mexico, including group health coverage, individual health insurance policies, health maintenance organizations, and nonprofit health care plans, provide coverage for at least one injectable glucagon-like peptide-1 receptor agonist prescribed for chronic weight management in adults with obesity. The new legal language is inserted into various sections of the Health Care Purchasing Act, Chapter 59A, and the Health Maintenance Organization Law, ensuring that these requirements are uniformly applied across different types of health insurance plans.

The provisions of this act will take effect for all relevant health insurance policies, plans, and contracts that become effective on or after January 1, 2026. This legislation aims to improve access to necessary weight management treatments for adults struggling with obesity, thereby addressing a significant public health issue.